Substance / Medication

Afamelanotide

Overview

Active Ingredient
afamelanotide
RxNorm CUI
2262250

Indications

® SCENESSEis indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).

Labeler: CLINUVEL INC.Updated: 2026-02-02T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

SCENESSE SCENESSE is contraindicated in patients with a history of severe hypersensitivity reaction to afamelanotide or to any of the excipients in.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians.
Toh Joseph Jia Hong, Chuah Sai Yee, Jhingan Anjali et al. · J Am Acad Dermatol · 2020
PMID: 31987791RCT
The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study.
Kluijver Louisa G, Nekouei Shahraki Mitra, Wagenmakers Margreet A E M et al. · Br J Dermatol · 2024
PMID: 38634774Observational
Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide - a three years observational study.
Barman-Aksözen Jasmin, Nydegger Michèle, Schneider-Yin Xiaoye et al. · Orphanet J Rare Dis · 2020
PMID: 32811524ObservationalFull text (PMC)
Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.
Biolcati G, Marchesini E, Sorge F et al. · Br J Dermatol · 2015
PMID: 25494545Observational
Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.
Lim Henry W, Grimes Pearl E, Agbai Oma et al. · JAMA Dermatol · 2015
PMID: 25230094Observational
Afamelanotide for Erythropoietic Protoporphyria.
Langendonk Janneke G, Balwani Manisha, Anderson Karl E et al. · N Engl J Med · 2015
PMID: 26132941ObservationalFull text (PMC)
From darkness to light: Case report on afamelanotide-treatment in a 9-year-old child with erythropoietic protoporphyria.
Minder Anna-Elisabeth, Barman-Aksözen Jasmin · JAAD Case Rep · 2026
PMID: 41542313Case ReportFull text (PMC)
The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo.
Grimes Pearl E, Hamzavi Iltefat, Lebwohl Mark et al. · JAMA Dermatol · 2013
PMID: 23407924Case Report
Pseudoleucoderma after injections of afamelanotide in a patient with atopic dermatitis.
von Bartenwerffer Wibke, Siebenhaar Guido, Hunzelmann Nicolas · Acta Derm Venereol · 2011
PMID: 21597671Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Afamelanotide (substance)
SNOMED CT
819968004
UMLS CUI
C2607750
RxNorm CUI
2262250
Labeler
CLINUVEL INC.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.